Cargando…
Drugs Associated With the Development of Palmoplantar Keratoderma: A Systematic Review
BACKGROUND: Palmoplantar keratoderma (PPK) are a heterogenous group of hereditary and acquired disorders that are characterized by excessive epidermal thickening of the palms and/or soles. PPK has been described as a rare adverse event for some medications. The aim of this systematic review was to s...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474319/ https://www.ncbi.nlm.nih.gov/pubmed/33779326 http://dx.doi.org/10.1177/12034754211004560 |
_version_ | 1784575186776883200 |
---|---|
author | Mirali, Sara Abduelmula, Abrahim Mufti, Asfandyar Sachdeva, Muskaan Yeung, Jensen |
author_facet | Mirali, Sara Abduelmula, Abrahim Mufti, Asfandyar Sachdeva, Muskaan Yeung, Jensen |
author_sort | Mirali, Sara |
collection | PubMed |
description | BACKGROUND: Palmoplantar keratoderma (PPK) are a heterogenous group of hereditary and acquired disorders that are characterized by excessive epidermal thickening of the palms and/or soles. PPK has been described as a rare adverse event for some medications. The aim of this systematic review was to summarize outcomes in PPK associated with various medications. This data will assist dermatologists and other healthcare providers treating patients with drug-induced PPK. METHODS: EMBASE and MEDLINE databases were searched in accordance with PRISMA guidelines using the keyword “palmoplantar keratoderma.” 40 studies met the inclusion criteria. RESULTS: A total of 247 patients (mean age: 57.0 years) were included in the analysis. Among patients whose sex was reported, 60.3% (n = 35/58) were male. PPK most frequently developed after treatment with BRAF inhibitors (73.7%, n = 182/247), BRAF inhibitors combined with MEK1/2 inhibitors (15.4%, n = 38/247), tyrosine kinase inhibitors (TKIs) (3.2%, n = 8/247), or chemotherapy (2.4%, n = 6/247). The mean latency period between initiation of the drug and onset of PPK was 7.6 months (range: 0.25-90 months). Improvement of PPK was reported in 24 cases, with 50% (n = 12/24) achieving complete resolution and 50% (n = 12/24) achieving partial resolution. All patients who achieved complete resolution stopped the suspected drug, with a mean resolution period of 2.4 months (range: 2 weeks-6 months). The most common treatments for PPK were keratolytic treatments (n = 10) and topical corticosteroids (n = 4). CONCLUSIONS: PPK was most frequently associated with targeted kinase inhibitors, specifically BRAF, MEK1/2, and tyrosine kinase inhibitors. |
format | Online Article Text |
id | pubmed-8474319 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-84743192021-09-28 Drugs Associated With the Development of Palmoplantar Keratoderma: A Systematic Review Mirali, Sara Abduelmula, Abrahim Mufti, Asfandyar Sachdeva, Muskaan Yeung, Jensen J Cutan Med Surg Review Articles BACKGROUND: Palmoplantar keratoderma (PPK) are a heterogenous group of hereditary and acquired disorders that are characterized by excessive epidermal thickening of the palms and/or soles. PPK has been described as a rare adverse event for some medications. The aim of this systematic review was to summarize outcomes in PPK associated with various medications. This data will assist dermatologists and other healthcare providers treating patients with drug-induced PPK. METHODS: EMBASE and MEDLINE databases were searched in accordance with PRISMA guidelines using the keyword “palmoplantar keratoderma.” 40 studies met the inclusion criteria. RESULTS: A total of 247 patients (mean age: 57.0 years) were included in the analysis. Among patients whose sex was reported, 60.3% (n = 35/58) were male. PPK most frequently developed after treatment with BRAF inhibitors (73.7%, n = 182/247), BRAF inhibitors combined with MEK1/2 inhibitors (15.4%, n = 38/247), tyrosine kinase inhibitors (TKIs) (3.2%, n = 8/247), or chemotherapy (2.4%, n = 6/247). The mean latency period between initiation of the drug and onset of PPK was 7.6 months (range: 0.25-90 months). Improvement of PPK was reported in 24 cases, with 50% (n = 12/24) achieving complete resolution and 50% (n = 12/24) achieving partial resolution. All patients who achieved complete resolution stopped the suspected drug, with a mean resolution period of 2.4 months (range: 2 weeks-6 months). The most common treatments for PPK were keratolytic treatments (n = 10) and topical corticosteroids (n = 4). CONCLUSIONS: PPK was most frequently associated with targeted kinase inhibitors, specifically BRAF, MEK1/2, and tyrosine kinase inhibitors. SAGE Publications 2021-03-28 2021-09 /pmc/articles/PMC8474319/ /pubmed/33779326 http://dx.doi.org/10.1177/12034754211004560 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/This article is distributed under the terms of the Creative Commons Attribution 4.0 License (https://creativecommons.org/licenses/by/4.0/) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Review Articles Mirali, Sara Abduelmula, Abrahim Mufti, Asfandyar Sachdeva, Muskaan Yeung, Jensen Drugs Associated With the Development of Palmoplantar Keratoderma: A Systematic Review |
title | Drugs Associated With the Development of Palmoplantar Keratoderma: A
Systematic Review |
title_full | Drugs Associated With the Development of Palmoplantar Keratoderma: A
Systematic Review |
title_fullStr | Drugs Associated With the Development of Palmoplantar Keratoderma: A
Systematic Review |
title_full_unstemmed | Drugs Associated With the Development of Palmoplantar Keratoderma: A
Systematic Review |
title_short | Drugs Associated With the Development of Palmoplantar Keratoderma: A
Systematic Review |
title_sort | drugs associated with the development of palmoplantar keratoderma: a
systematic review |
topic | Review Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474319/ https://www.ncbi.nlm.nih.gov/pubmed/33779326 http://dx.doi.org/10.1177/12034754211004560 |
work_keys_str_mv | AT miralisara drugsassociatedwiththedevelopmentofpalmoplantarkeratodermaasystematicreview AT abduelmulaabrahim drugsassociatedwiththedevelopmentofpalmoplantarkeratodermaasystematicreview AT muftiasfandyar drugsassociatedwiththedevelopmentofpalmoplantarkeratodermaasystematicreview AT sachdevamuskaan drugsassociatedwiththedevelopmentofpalmoplantarkeratodermaasystematicreview AT yeungjensen drugsassociatedwiththedevelopmentofpalmoplantarkeratodermaasystematicreview |